Read the full release \u2192<\/a><\/p>\nNews provided by PR Newswire.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"MUNICH, June 25, 2026 \/PRNewswire\/ — Innovative Molecules GmbH, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, today announced that the first patient has been dosed in its Phase 2a clinical trial evaluating\u2026<\/p>\n","protected":false},"author":14,"featured_media":2110,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-2109","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-art-community"],"yoast_head":"\n
Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development - Ciel Charlotte<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development - Ciel Charlotte\" \/>\n<meta property=\"og:description\" content=\"MUNICH, June 25, 2026 \/PRNewswire\/ -- Innovative Molecules GmbH, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, today announced that the first patient has been dosed in its Phase 2a clinical trial evaluating\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Ciel Charlotte\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-25T06:20:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"384\" \/>\n\t<meta property=\"og:image:height\" content=\"253\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ethan Parker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ethan Parker\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\\\/\"},\"author\":{\"name\":\"Ethan Parker\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\"},\"headline\":\"Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development\",\"datePublished\":\"2026-06-25T06:20:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\\\/\"},\"wordCount\":64,\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development-ai.png\",\"articleSection\":[\"Art Community\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\\\/\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\\\/\",\"name\":\"Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development - Ciel Charlotte\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development-ai.png\",\"datePublished\":\"2026-06-25T06:20:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development-ai.png\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development-ai.png\",\"width\":1536,\"height\":1024,\"caption\":\"Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\",\"name\":\"Ciel Charlotte\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\",\"name\":\"Ethan Parker\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"caption\":\"Ethan Parker\"},\"description\":\"Ethan Parker covers stories about community life, personal well-being, local initiatives, lifestyle trends, and the people working to create stronger communities. His writing looks for the human element behind larger developments, focusing on practical ideas and meaningful stories. Ethan brings an approachable perspective to subjects involving everyday life, community participation, creativity, and social connection.\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/author\\\/ethan-parker\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development - Ciel Charlotte","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development - Ciel Charlotte","og_description":"MUNICH, June 25, 2026 \/PRNewswire\/ -- Innovative Molecules GmbH, a late-stage clinical biotechnology company focused on the development of differentiated antiviral therapies, today announced that the first patient has been dosed in its Phase 2a clinical trial evaluating\u2026","og_url":"https:\/\/development.brstdev.com\/cielcharlotte\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\/","og_site_name":"Ciel Charlotte","article_published_time":"2026-06-25T06:20:00+00:00","og_image":[{"width":384,"height":253,"url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg","type":"image\/jpeg"}],"author":"Ethan Parker","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ethan Parker"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\/#article","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\/"},"author":{"name":"Ethan Parker","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450"},"headline":"Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development","datePublished":"2026-06-25T06:20:00+00:00","mainEntityOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\/"},"wordCount":64,"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development-ai.png","articleSection":["Art Community"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\/","url":"https:\/\/development.brstdev.com\/cielcharlotte\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\/","name":"Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development - Ciel Charlotte","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website"},"primaryImageOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\/#primaryimage"},"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development-ai.png","datePublished":"2026-06-25T06:20:00+00:00","author":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450"},"breadcrumb":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/development.brstdev.com\/cielcharlotte\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\/#primaryimage","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development-ai.png","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development-ai.png","width":1536,"height":1024,"caption":"Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development"},{"@type":"BreadcrumbList","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/innovative-molecules-announces-first-patient-dosed-in-phase-2a-trial-of-adibelivir-im-250-advancing-company-into-late-stage-clinical-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/development.brstdev.com\/cielcharlotte\/"},{"@type":"ListItem","position":2,"name":"Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development"}]},{"@type":"WebSite","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website","url":"https:\/\/development.brstdev.com\/cielcharlotte\/","name":"Ciel Charlotte","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/development.brstdev.com\/cielcharlotte\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450","name":"Ethan Parker","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","caption":"Ethan Parker"},"description":"Ethan Parker covers stories about community life, personal well-being, local initiatives, lifestyle trends, and the people working to create stronger communities. His writing looks for the human element behind larger developments, focusing on practical ideas and meaningful stories. Ethan brings an approachable perspective to subjects involving everyday life, community participation, creativity, and social connection.","url":"https:\/\/development.brstdev.com\/cielcharlotte\/author\/ethan-parker\/"}]}},"_links":{"self":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/2109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/comments?post=2109"}],"version-history":[{"count":1,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/2109\/revisions"}],"predecessor-version":[{"id":9460,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/2109\/revisions\/9460"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media\/2110"}],"wp:attachment":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media?parent=2109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/categories?post=2109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/tags?post=2109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}